论文部分内容阅读
目的通过检测泛素偶联酶2C(UBE2C)在神经母细胞瘤(NB)患儿中的表达情况,分析其表达与NB患儿的临床特征及预后的相关性。方法收集上海交通大学医学院附属新华医院2012年1月至2015年1月51例NB患儿术后石蜡包埋的组织样本,通过免疫组织化学方法检测其UBE2C蛋白的表达水平。回顾性分析NB患儿的临床特征,采用Kaplan-Meier法分析其生存曲线。结果 51例患儿中,男女比例为1.8∶1,中位诊断年龄为36个月(3.3~156.0个月),中位随访时间为25.6个月(5.5~42.7个月)。免疫组化结果显示,Ⅲ、Ⅳ期患儿UBE2C蛋白表达的阳性率(90.0%)明显高于Ⅰ、Ⅱ、Ⅳs期患儿(47.6%)(P<0.001);复发NB患儿的UBE2C表达阳性率(91.3%)明显高于无复发者(57.1%)(P=0.001)。生存曲线分析显示,UBE2C蛋白阳性表达组预后较差(P=0.006)。结论 UBE2C的表达与NB的分期及复发密切相关,UBE2C表达阳性提示NB患儿预后不良。UBE2C可能在NB侵袭、转移和复发过程中发挥重要的作用,有望成为NB潜在的生物标记物和治疗新靶点。
Objective To detect the expression of ubiquitin-conjugating enzyme 2C (UBE2C) in children with neuroblastoma (NB) and analyze its correlation with the clinical characteristics and prognosis of children with NB. Methods Totally 51 paraffin-embedded tissue samples of 51 children with NB were collected from Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and the expression of UBE2C protein was detected by immunohistochemistry. The clinical features of children with NB were analyzed retrospectively. The survival curves were analyzed by Kaplan-Meier method. Results Among 51 children, the ratio of male to female was 1.8: 1. The median age of diagnosis was 36 months (3.3-156.0 months). The median follow-up time was 25.6 months (5.5-42.7 months). Immunohistochemical results showed that the positive rate of UBE2C protein expression in stage Ⅲ, Ⅳ was significantly higher than that in stage Ⅰ, Ⅱ, Ⅳs (47.6%) (P <0.001); UBE2C expression in relapsed NB The positive rate (91.3%) was significantly higher than those without recurrence (57.1%) (P = 0.001). Survival curve analysis showed that UBE2C positive expression group had poor prognosis (P = 0.006). Conclusion The expression of UBE2C is closely related to the staging and recurrence of NB. The positive expression of UBE2C suggests that the prognosis of NB is poor. UBE2C may play an important role in the process of NB invasion, metastasis and relapse and is expected to become a potential biomarker of NB and a new therapeutic target.